The National Institutes of Health proposed a new policy Dec. 3 that would require multi-site studies it funds to only go through a single institutional review board rather than multiple, local IRB reviews, except in special cases.
When human subject protections were first put in place, most clinical research was conducted at a single institution, the agency notes. Since then, clinical trials have become more complex, requiring...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?